With the release of the list of rare disease in China, the economic evaluation of drug use for rare disease is also gradually advancing. Rare disease is characterized by insufficient cognition and basic research, difficult diagnosis, difficult evaluation of therapeutic effect and difficult patients recruitments. Clinical studies on the use of rare diseases also have problems such as non-random design and short follow-up period, which increase the difficulty of pharmacoeconomic evaluation. In pharmacoeconomic evaluation of drugs for rare disease, problems may occur, such as difficulty in selecting reference drugs, uncertainty in model structure, difficulty and high uncertainty in obtaining efficacy data, safety data, cost and health utility parameters. Based on the above problems and challenges, this paper put forward countermeasures that could be taken by all stakeholders in China, so as to make a more objective and reasonable economic evaluation of drug use for rare disease, and reduced the uncertainty of results and decision-making uncertainty of medical insurance departments.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |